Wei C Lau

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Clopidogrel-drug interactions
    Eric R Bates
    Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Am Coll Cardiol 57:1251-63. 2011
  2. ncbi Intraoperative transesophageal echocardiographic assessment of the effect of protamine on paraprosthetic aortic insufficiency immediately after stentless tissue aortic valve replacement
    Wei C Lau
    Department of Anesthesiology, University of Michigan, Ann Arbor 48109, USA
    J Am Soc Echocardiogr 15:1175-80. 2002
  3. ncbi Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction
    Wei C Lau
    Department of Anesthesiology, University of Michigan, Ann Arbor, USA
    Circulation 107:32-7. 2003
  4. ncbi Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
    Wei C Lau
    Department of Anesthesiology, University of Michigan Health System, 1G323 University Hospital, Box 0048, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0048, USA
    Circulation 109:166-71. 2004
  5. ncbi The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity
    Wei C Lau
    Cardiovascular Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI 48109 5861, USA
    J Cardiovasc Pharmacol 57:86-93. 2011
  6. ncbi Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4
    Wei C Lau
    Medical Director Cardiovascular Center Operating Rooms, Cardiovascular Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Pharm Res 23:2691-708. 2006
  7. ncbi Controversies in antiplatelet therapy for patients with cardiovascular disease
    Eric R Bates
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich, USA
    Circulation 111:e267-71. 2005
  8. ncbi Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes
    Haoming Zhang
    Department of Pharmacology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 5632, USA
    Mol Pharmacol 82:302-9. 2012
  9. ncbi Perioperative practice: time to throttle back
    Vineet Chopra
    University of Michigan Health System, Ann Arbor, Michigan 48109 5853, USA
    Ann Intern Med 152:47-51. 2010
  10. ncbi Loading, pretreatment, and interindividual variability issues with clopidogrel dosing
    Eric R Bates
    Circulation 111:2557-9. 2005

Detail Information

Publications14

  1. ncbi Clopidogrel-drug interactions
    Eric R Bates
    Division of Cardiovascular Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Am Coll Cardiol 57:1251-63. 2011
    ....
  2. ncbi Intraoperative transesophageal echocardiographic assessment of the effect of protamine on paraprosthetic aortic insufficiency immediately after stentless tissue aortic valve replacement
    Wei C Lau
    Department of Anesthesiology, University of Michigan, Ann Arbor 48109, USA
    J Am Soc Echocardiogr 15:1175-80. 2002
    ..Protamine administration is associated with resolution of small AI jets immediately after implantation of a stentless aortic bioprosthesis, with a jet width 0.3 cm or less strongly predictive of resolution...
  3. ncbi Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction
    Wei C Lau
    Department of Anesthesiology, University of Michigan, Ann Arbor, USA
    Circulation 107:32-7. 2003
    ..Because atorvastatin is metabolized by cytochrome P450 (CYP) 3A4, we hypothesized that clopidogrel might be activated by CYP3A4...
  4. ncbi Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
    Wei C Lau
    Department of Anesthesiology, University of Michigan Health System, 1G323 University Hospital, Box 0048, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0048, USA
    Circulation 109:166-71. 2004
    ..Because the prodrug clopidogrel is activated by hepatic cytochrome P450 (CYP) 3A4, we hypothesized that interindividual variability in clopidogrel efficacy might be related to interindividual differences in CYP3A4 metabolic activity...
  5. ncbi The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity
    Wei C Lau
    Cardiovascular Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI 48109 5861, USA
    J Cardiovasc Pharmacol 57:86-93. 2011
    ..0002) and increased platelet inhibition (23% ± 11% vs. 41% ± 16%, P = 0.002). SJW may be a future therapeutic option to increase CYP metabolic activity and antiplatelet effect of clopidogrel in hyporesponders...
  6. ncbi Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4
    Wei C Lau
    Medical Director Cardiovascular Center Operating Rooms, Cardiovascular Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Pharm Res 23:2691-708. 2006
    ..Further investigation or guidelines are needed to optimize antiplatelet treatment strategies to identify and treat patients resistant to aspirin and/or clopidogrel...
  7. ncbi Controversies in antiplatelet therapy for patients with cardiovascular disease
    Eric R Bates
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich, USA
    Circulation 111:e267-71. 2005
  8. ncbi Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes
    Haoming Zhang
    Department of Pharmacology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 5632, USA
    Mol Pharmacol 82:302-9. 2012
    ..These factors may affect the effective concentrations of the AM in vivo...
  9. ncbi Perioperative practice: time to throttle back
    Vineet Chopra
    University of Michigan Health System, Ann Arbor, Michigan 48109 5853, USA
    Ann Intern Med 152:47-51. 2010
    ..Our society demands better care at lower cost; in perioperative medicine, it is time for us to throttle back...
  10. ncbi Loading, pretreatment, and interindividual variability issues with clopidogrel dosing
    Eric R Bates
    Circulation 111:2557-9. 2005
  11. ncbi Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel
    Paul A Gurbel
    J Am Coll Cardiol 51:261-3. 2008
  12. ncbi Clinical significance of the atorvastatin-clopidogrel drug-drug interaction
    Wei C Lau
    Circulation 110:e66-7; author reply e66-7. 2004
  13. ncbi Drug-drug interactions involving antiplatelet agents
    Eric R Bates
    Eur Heart J 24:1707-9. 2003
  14. ncbi Clopidogrel resistance: implications for coronary stenting
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    Curr Pharm Des 12:1261-9. 2006
    ..The mechanisms of the response variability to clopidogrel remain incompletely defined. The contribution of intra- and extracellular pathways are under investigation...